Canadian and European health agencies thoughts about Invokana

Canadian and European health agencies thoughts about Invokana

European and Canadia health agencies have recently initiated safety reviews for Invokana and other sodium-glucose cotransporter-2 (SGLT2) inhibitors after reports linked the sort 2 diabetes drug to serious side effects. The actions by the ecu Medicines Agency (EMA) and Health Canada come after the U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication on May 15, 2015, warning that Invokana could also be linked to an increased risk of ketoacidosis and other serious health conditions.

Ketoacidosis may be a ill health where the body produces too many blood acids. In serious cases, sufferers of ketoacidosis may require hospitalization. Invokana and other SGLT2 inhibitors are prescribed to treat type 2 diabetes. Invokana forces the kidneys to expel excess blood glucose through urine. Complications related to ketoacidosis include Kussmaul’s coma , difficulty breathing, nausea, confusion, and fatigue.

Health Canada’s said it’ll review Invokana (canagliflozin) and Forxiga (dapagliflozin) to work out if any changes to prescribing information got to be made. Health Canada’s review will evaluate any links between taking SGLT2 inhibitors like Invokana and developing ketoacidosis.

The European Medicines Agency’s review of Invokana was requested by the ecu Commision after quite 100 incidents of great injuries linked to taking the sort 2 diabetes drug were reported. the ecu Medicines Agency will evaluate all the medical data available about the danger between Invokana and developing ketoacidosis. the ecu Medicines Agency’s may issue a ruling affecting the way Invokana and other SGLT2 inhibitors are prescribed within the European Union .

In addition to developing ketoacidosis, Invokana could also be linked to other serious medical conditions like attack , stroke, and renal failure . Patients taking Invokana and other SGLT2 inhibitors are advised to consult their doctors before making any changes to their diabetes medications and report any serious complications while taking the drug.

Please call 1-800-THE-FIRM (843-3476) or fill out a contact form to receive a free, confidential, and prompt Invokana case review. Because strict time deadlines apply, please contact us at your earliest convenience so as to preserve your rights.

Leave a Reply

Your email address will not be published. Required fields are marked *